See our video services!
At The Guide Liverpool, we’ve been helping businesses promote themselves and reach new clients and customers for years. Our professional video crew can help you increase engagement, interaction and revenue by presenting your business to a wide audience with a creative, exciting promotional video for use on multiple online channels.
Some European countries have restricted the vaccine use in younger people following reports of cerebral venous sinus thrombosis (CVST) – a specific type of clot that prevents blood from draining from the brain, as well as low platelet counts – cells that help blood clot.
On Tuesday, it was announced that the trial of the Oxford/AstraZeneca vaccine in children has been paused while UK regulator the Medicines and Healthcare products Regulatory Agency (MHRA) investigates the CVST reports.
Meanwhile, Prime Minister Boris Johnson has said people should keep getting their jabs.
According to the most recent MHRA update, 30 cases of CVST and seven deaths were reported in the UK among more than 18.1 million people receiving the jab.
There have also been reports of CVST cases in Germany and cases of blood clot clusters in Norway, the Netherlands and Denmark but experts say these incidents are rare.
🍾RT/ LIKE/ REPLY with one thing you are missing about the Randox Grand National Festival.
— The Guide Liverpool (@TheGuideLpool) April 6, 2021
Germany, France, the Netherlands, Sweden and Canada have restricted the use of the AstraZeneca vaccine in younger people while Denmark and Norway have paused administering it.
But several European countries – such as Greece, Italy and Portugal – are using the vaccine without such restrictions.
The MHRA and the European Medicines Agency (EMA) have both said there is no evidence to suggest the vaccine has caused these rare blood clots, although they are continuing to monitor the situation.
While a definitive link cannot be ruled out, the regulators said the benefits of having the vaccine far outweigh any potential risks.
The MHRA and the EMA are expected to give updates on their investigations into whether the AstraZeneca vaccine is directly causing these rare blood clots.
AstraZeneca has said it will continue to analyse its database to understand “whether these very rare cases of blood clots associated with thrombocytopenia (low blood platelet count) occur any more commonly than would be expected naturally in a population of millions of people”.
Meanwhile on Tuesday, a trial of the Oxford/AstraZeneca vaccine on children was paused, but the scientists involved said there were no safety concerns with the trial itself and they were waiting for further information from the MHRA.
The University of Oxford said in a statement: “Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA on its review of rare cases of thrombosis/thrombocytopaenia that have been reported in adults, before giving any further vaccinations in the trial.”
Scientists in the UK have been largely in agreement with the regulators, saying the benefits of the vaccine outweigh potential risks.
Professor Adam Finn, from the University of Bristol and a member of the Joint Committee on Vaccination and Immunisation (JCVI), said it was vital to keep vaccines going as society opens up, in order to help stave off rising infection rates.
He urged people being offered the vaccine at the moment to take it, saying the “risk-benefit is very strongly in favour of receiving the vaccine”.
Professor Calum Semple, a member of the Scientific Advisory Group for Emergencies (Sage), which advises ministers, said he was “not worried one little bit” about headlines around the AstraZeneca vaccine.
Speaking in a personal capacity, he told LBC radio: “I’ll take (it) myself, I’m 53, my risk of death from Covid is about one in 13,000, for me it’s a no-brainer, I need to have the vaccine.”
Meanwhile, former MHRA chief Professor Sir Kent Woods also told LBC radio: “Covid itself – the infection itself – is known to be associated with a substantial increased risk of blood clots of various kinds.
“At a time when the population has got lots of Covid going around, it’s very difficult to know what the actual background rate of these clotting events is without the vaccine.
“We can say I think that if there is a connection, it’s a very, very rare one.”
The UK is currently using two vaccines, Pfizer/BioNTech and Oxford/AstraZeneca, while a third coronavirus vaccine, the Moderna jab, began its rollout in Wales on Wednesday.
Meanwhile, preliminary results announced on Tuesday from the trials of the Valneva Covid-19 vaccine, which is set to be manufactured in the UK, has shown it produces a “strong immune response”, paving the way for a phase three clinical trial.
The UK has an in-principle agreement for 60 million doses of the Valneva jab, with an option to acquire a further 130 million doses from 2022-2025.
The country has also ordered 30 million doses of a coronavirus vaccine developed by Johnson & Johnson, which has been shown to be 66% effective in preventing coronavirus infection.
Both the Valneva and Johnson & Johnson jabs will need regulatory approval for use in the UK, once data from later-stage trials become available.
Sign up with us to receive the latest news, straight to your inbox!
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
|cookielawinfo-checbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.